Organization & Developments: Regeneron (Archives 2014-2016)

Parents

2014: Regeneron, Bayer to co-develop Eylea combination treatment (2014)
2015: Cholesterol drug Praluent approved by FDA
2015: Regeneron Recovers From Clinton Biotech Beat Down
2015: Regeneron speeds toward the FDA with its would-be asthma blockbuster
2016: Regeneron - A Review: Strong Returns Look Likely For 2016 And Beyond - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
2016: Regeneron Disappoints, The Stock Sells Off: Analysis Of Its Growth Potential - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
2016: Regeneron Generates Negative Alpha: Buy, Sell Or Hold? - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
2016: Regeneron On The Radar For Biotech - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
2016: Regeneron-Sanofi Drug Clears Eczema, Sparks Debate On Market Size
2016: Regeneron: The Amazon Of Biotech? - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
2016: Regeneron's Q2: Opportunities And Challenges - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
2016: Regeneron/Sanofi Drug Beats Humira In Rheumatoid Arthritis Trial
2016: Will Regeneron's Lead Drug Eylea Be Harmed By New Data? Analysis - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)